Intermedin reduces neointima formation by regulating vascular smooth muscle cell phenotype via cAMP/PKA pathway. (November 2017)

• Record Type: Journal Article
• Authors: Zhu, Qing; Ni, Xian-Qiang; Lu, Wei-Wei; Zhang, Jin-Sheng; Ren, Jin-Ling; Wu, Di; Chen, Yao; Zhang, Lin-Shuang; Yu, Yan-Rong; Tang, Chao-Shu; Qi, Yong-Fen
• Is Part Of: Atherosclerosis. Volume 266(2017)
• Page Start: 212
• Page End: 222
• Publication Date: 2017-11
• Subjects: Intermedin -- Vascular smooth muscle cell -- Phenotype modulation -- Neointima formation -- cAMP/PKA pathway; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2017.10.011
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: Vascular smooth muscle cell (VSMC) dedifferentiation contributes to neointima formation, which results in various vascular disorders. Intermedin (IMD), a cardiovascular paracrine/autocrine polypeptide, is involved in maintaining circulatory homeostasis. However, whether IMD protects against neointima formation remains largely unknown. The purpose of this study is to investigate the role of IMD in neointima formation and the possible mechanism. Methods: IMD1-53 (100ng/kg/h) or saline water was used on rat carotid-artery balloon-injury model. The mouse left common carotid-artery ligation-injury model was established using IMD-transgenic and C57BL/6J mice. Immunohistochemistry and immunofluorescence staining was used to detect the protein expression in rat carotid arteries. Radioimmunoassay was used to determine the serum IMD level. The hematoxylin andeosin staining was used for carotid arteries morphological testing. In vitro, for rat primary cultured VSMC phenotype transition, proliferation and migration assays, platelet-derived growth factor-BB (PDGF-BB) reagent and IMD1-53 peptide were added to the culture media at the final concentration of 20 ng/mL and 10 -7 mol/L respectively. Quantification of VSMC proliferation involved MTT and BrdU assay and migration was detected by wound-healing assay. Western blot and realtime PCR were used to detect the protein and mRNA levels of tissues or cells. Results: With the rat carotid-artery balloon-injury model, IMD was significantly downregulated in injured arteries and plasma. Exogenous IMD1-53 greatly inhibited neointima formation and prevented VSMC from switching to a synthetic phenotype. With the left common carotid-artery ligation-injury model, IMD-transgenic mice showed less neointima formation than C57BL/6J mice. PDGF-BB reduced IMD mRNA expression in rat primary cultured VSMCs but increased that of its receptors, calcitonin receptor-like receptor or receptor activity-modifying proteins. Furthermore, PDGF-BB promoted VSMC proliferation and migration and transformed VSMCs to the synthetic phenotype, which was reversed with IMD1-53 treatment. Mechanistically, IMD1-53 maintained the contractile VSMC phenotype via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. Conclusions: IMD attenuated neointima formation both in the rat model of carotid-artery balloon injury and mouse model of common carotid-artery ligation injury. IMD protection may be mediated by maintaining a VSMC contractile phenotype via the cAMP/PKA pathway. Highlights: IMD is reduced in injured vessels and plasma in vivo and in VSMC with PDGF-BB treatment in vitro . IMD attenuates neointima formation in the rat model of carotid-artery balloon injury and in the mouse model of carotid-artery ligation injury. IMD1-53 attenuates VSMC proliferation, migration and synthetic phenotype. IMD1-53 maintains the VSMC contractile phenotype by the cyclic adenosine monophosphate/protein kinase A pathway.